Michael Morrison
Senior Researcher in Social Science
Biography
Michael has an MA (by Research and Thesis) and PhD from the interdisciplinary Institute for Science and Society (ISS) at the University of Nottingham. He also holds a BSc in Biology from the University of St. Andrews (2000). Michael has recently acted as Principal Investigator on the ESRC-funded project 'Biomodifying technologies and experimental space’, (2017-2020) and is now working on the 'sister' prohect BioGov: Governing biomodification in the life sciences' with professor Kaye. Both projects involve collaboration between researchers from the Universities of Oxford, Sussex and York to examine three '‘gateway technologies’ with wide-ranging applications in medicine and the life sciences; gene editing, induced pluripotent stem cells, and 3D printing of living material. Each of these technologies enables researchers to modify living biological tissue in novel and increasingly patient-orientated and customized ways, which challenge the suitability of traditional manufacturing, governance and reimbursement pathways designed for small molecule pharmaceuticals or medical devices.
Michael has previously worked on the IMI STEMBANCC project at Oxford (2012-2017), providing governance and ethical support to this European public-private partnership in stem cell biobanking. He has also been a researcher on the European Framework Programme 7 'Regenerative Medicine in Europe' (REMEDiE) project at the University of York and with the Health Technology and Society group at the University of Exeter. More details his research, review activity and publications can be found via ResearchGate and his ORCID profile.
Featured Publications
Publications
Bicudo E, Morrison M, Li P, Faulkner A, Webster A, Mourby M and Kaye J, “Patent Power in Biomedical Innovation: Technology Governance in Biomodifying Technologies” (2022) 25 Journal of World Intellectual Property 473
Morrison M and Bartlett A, “Making Translational Value: Identifying ‘good targets’ for Clinical Research on Gene Editing and Induced Pluripotent Stem Cell Technologies” (2022) 2 SSM - Qualitative Research in Health
Mourby M, Bell J, Morrison M, Faulkner A, Li P, Bicudo E, Webster A and Kaye J, “Biomodifying the ‘natural’: From Adaptive Regulation to Adaptive Societal Governance” (2022) 9 Journal of Law and the Biosciences
Bin Abdul Aziz M, Morrison M and Kaye J, “Creative Regulatory Practices to Develop Stem-Cell Technology: The Way Forward for Malaysia”. (2022) 17 Regenerative medicine 91
Morrison M, “The Matrix of Stem Cell Research: An Approach to Rethinking Science in Society” (2022) 41 NEW GENETICS AND SOCIETY 358
Takashima K, Morrison M and Minari J, “Reflection on the Enactment and Impact of Safety Laws for Regenerative Medicine in Japan” (2021) 16 Stem Cell Reports 1425
Umemura M and Morrison M, “Comparative Lessons in Regenerative Medicine Readiness: Learning from the UK and Japanese Experience” (2021) 16 Regenerative Medicine 269
Morrison M, Stephens N, Martin P and Hogle L, “Spatiotemporal Readiness Is Key to Preparing Regenerative Medicine for the Clinic” (2021) 16 Regenerative Medicine 229
Morrison M, Mourby M, Gowans H, Coy S and Kaye J, “Governance of Research Consortia: Challenges of Implementing Responsible Research and Innovation Within Europe” (2020) 16 Life Sciences, Society and Policy
Morrison M, “Making Bio-Objects Mobile: Behind the Scenes of a Translational Stem Cell Banking Consortium” (2020) 17 BioSocieties 145
Martin P, Morrison M, Turkmendag I, Nerlich B, McMahon A, deSaille S and Barlett A, “Genome Editing: The Dynamics of Continuity, Convergence, and Change in the Engineering of Life” [2020] New Genetics and Society 1
Mourby M and Morrison M, “Gene Therapy Regulation: Could in-Body Editing Fall through the Net?” (2020) 28 European Journal of Human Genetics 979
Morrison M and De Saille S, “CRISPR in Context: Towards a Socially Responsible Debate on Embryo Editing” (2019) 5 Palgrave Communications
Feeney O, Cockbain J, Morrison M, Diependaele L, Van Assche K and Sterckx S, “Patenting Foundational Technologies: Lessons from CRISPR and Other Core Biotechnologies” (2018) 18 American Journal of Bioethics 36
Morrison M, “Valuing Height: Diagnosis, Valuation and the Case of Idiopathic Short Stature” (2018) 41 Sociology of Health and Illness 502
Morrison M, “Making Cells Worthwhile: Calculations of Value in a European Consortium for Induced Pluripotent Stem Cell Banking” (2018) 28 Science as Culture 46
Minari J, Brothers K and Morrison M, “Tensions in Ethics and Policy Created by National Precision Medicine Programs” (2018) 12 Human Genomics
Kaye J, Terry S, Juengst E, Coy S, Chalmers D, Dove E, Budin-Ljøsne I, Adebamowo C, Ogbe E, Bezuidenhout L, Morrison M, Minion J, Murtagh M, Minari J, Teare H, Isasi R, Kato K, Rial-Sebbag E, Marshall P, Koenig B and Cambon-Thomsen A, “Including All Voices in International Data-Sharing Governance”. (2018) 12 Human Genomics 13
Bin Abdul Aziz M, Morrison M and Kaye J, “Regulating Human Stem Cell Research and Therapy in Low- and Middle-Income Countries: Malaysian Perspectives” (2017) 37 New Genetics and Society 2
Morrison M, Bell J, George C, Harmon S, Munsie M and Kaye J, “The European General Data Protection Regulation: Challenges and Considerations for IPSC Researchers and Biobanks” (2017) 12 Regenerative Medicine 693
Nicol D, Eckstein L, Morrison M, Sherkow J, Otlowski M, Whitton T, Bubela T, Burdon K, Chalmers D, Chan S, Charlesworth J, Critchley C, Crossley M, de Lacey S, Dickinson J, Hewitt A, Kamens J, Kato K, Kleiderman E, Kodama S, Liddicoat J, Mackey D, Newson A, Nielsen J and Wagner J, “Key Challenges in Bringing CRISPR-Mediated Somatic Cell Therapy into the Clinic” (2017) 9 Genome medicine 85
Morrison M, “‘A Good Collaboration Is Based on Unique Contributions from Each side’: Assessing the Dynamics of Collaboration in Stem Cell Science”. (2017) 13 Life Sciences, Society and Policy 7
Morrison M, “Infrastructural Expectations: Exploring the Promise of International Large-Scale Induced Pluripotent Stem Cell Banks” (2017) 36 New Genetics and Society 66
Morrison M, “Overdiagnosis, Medicalisation and Social Justice: Commentary on Carter Et Al (2016) ‘A Definition and Ethical Evaluation of overdiagnosis’” (2016) 42 Journal of Medical Ethics 720
Bezuidenhout L and Morrison M, “Between Scylla and Charybdis: Reconciling Competing Data Management Demands in the Life Sciences” (2016) 17 BMC Medical Ethics
Morrison M, Moraia L and Steele J, “Traceability in Stem Cell Research: From Participant Sample to Induced Pluripotent Stem Cell and Back”. (2016) 11 Regenerative medicine 73
Morrison M, Klein C, Clemann N, Collier D, Hardy J, Heisserer B, Cader M, Graf M and Kaye J, “StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium”. (2015) 11 Stem cell reviews 681
Teare H, Morrison M, Whitley E and Kaye J, “Towards ’Engagement 2.0’: Insights from a Study of Dynamic Consent With Biobank Participants” (2015) 1 Digital Health 1
Morrison M, “Growth Hormone, Enhancement and the Pharmaceuticalisation of Short Stature”. (2015) 131 Social science & medicine (1982) 305
Kaye J, Whitley E, Lund D, Morrison M, Teare H and Melham K, “Dynamic Consent: A Patient Interface for Twenty-First Century Research Networks”. (2015) 23 European journal of human genetics : EJHG 141
Morrison M, “STS and Enhancement Technologies: A Programme for Future Research” (2015) 28 SCIENCE AND TECHNOLOGY STUDIES 3
Melham K, Moraia L, Mitchell C, Morrison M, Teare H and Kaye J, “The Evolution of Withdrawal: Negotiating Research Relationships in Biobanking”. (2014) 10 Life sciences, society and policy 16
Morrison M, “Me Medicine Vs. We Medicine: Reclaiming Biotechnology for the Common Good” (2013) 32 NEW GENETICS AND SOCIETY 454
Morrison M and Cornips L, “Exploring the Role of Dedicated Online Biotechnology News Providers in the Innovation Economy” (2012) 37 SCIENCE TECHNOLOGY & HUMAN VALUES 262
Morrison M, “Promissory Futures and Possible Pasts: The Dynamics If Contemporary Expectations in Regenerative Medicine” (2012) 7 BIOSOCIETIES 3
Bahadur G, Morrison M and Machin L, “Beyond the ’embryo question’: Human Embryonic Stem Cell Ethics in the Context of Biomaterial Donation in the UK”. (2010) 21 Reproductive biomedicine online 868
Bahadur G and Morrison M, “Patenting Human Pluripotent Cells: Balancing Commercial, Academic and Ethical Interests”. (2010) 25 Human reproduction (Oxford, England) 14
Morrison M, “Human Tissue” 1197
Morrison M and Kelly S, “Personalised Medicine”, Routledge International Handbook of Critical Issues in Health and Illness (Routledge 2021)
Morrison M, Teare H, Bertier G, Buchanan J, Bylstra Y, Gaff C, Jackson L, Kato K, Kaufmann E, Kelly S, Lazaro-Munoz G, Leitsalu L, Milani L, Schaefer G, Schickhardt C, Shabani M, Tutty E, Winkler E and Wordsworth S, “Implications of Secondary Findings for Clinical Contexts”, SECONDARY FINDINGS IN GENOMIC RESEARCH (2020)
Morrison M, Hogarth S and Kewell B, “Biocapital and Innovation Paths: The Exploitation of Regenerative Medicine” in A Webster (ed.), The Global Dynamics of Regenerative Medicine: A Social Science Critique (Palgrave Macmillan 2013)
Morrison M, “(Genome) Editing Future Societies” in P Martin, S De Saille, K Liddiard and W Pearce (eds.), Being Human During Covid-19 (Bristol University Press)
Gardner J and Morrison M, “Australia’s Medical Innovation Approach: Is It Suitable for Regenerative Medicine?”
Morrison M and Umemura M, “Japan: A Case Study of National ’readiness’ for Regenerative Medicine”
Morrison M, “The Promises and Challenges of Biomodifying Technologies for the UK”
Morrison M, Mourby M, Bartlett A and Bicudo E, “Biomodifying Technologies and Experimental Space: Organisational and Regulatory Implications for the Translation and Valuation of Health Research”
Morrison M, “Report from the Joint MHRA Patient Forum on Biomodifying Technologies” (2021)
Morrison M, Kaye J, Faulkner A, Li P, Webster A and Bartlett A, “Biomodifying Technologies Policy Briefing 3 ‘Trends in Customisation and Personalisation of Advanced therapies’” (2021)
Morrison M, Kaye J, Faulkner A, Li P, Webster A and Bartlett A, “Biomodifying Technologies Policy Briefing 2 ‘Accelerating Innovation: Speed and Timing in Translational research’” (2020)
Morrison M, Kaye J, Faulkner A, Li P, Webster A and Bartlett A, “Biomodifying Technologies Policy Briefing 1 ‘Making Good Targets for Translational research’” (2020)
Morrison M, “Research Using Free Text Data in Medical Records Could Benefit from Dynamic Consent and Other Tools for Responsible Governance” (2020) 380
Feeney O, Cockbain J, Morrison M, Diependaele L, Van Assche K and Sterckx S, “Response to Open Peer Commentaries on ‘Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies’”. (2019) W10
Morrison M, “Stem Cell Tourism and the Political Economy of Hope” (2018) 1434
Morrison M, Dickenson D and Lee S, “Introduction to the Article Collection ’Translation in Healthcare: Ethical, Legal, and Social implications’”. (2016) 1
Bell J, Bordag N, Borry P, Bovenberg J, Dagher G, Grewal J, Hoppe N, Isasi R, Kaye J, Knoppers B, Kwisda K, Morrison M, Neron A, Nys H, Oberauner-Wappis L, Rial-Sebbag E, Sandor J, Shabani M, Tournay V, Varju M and Zatloukal K, “Governing Stem Cells: Regenerative Medicine in Europe - the Vision and Recommendations from the EUCelLEX Project” (Genotoul Societal 2018)